Literature DB >> 11684144

Kinetic and mechanistic characterization of NMDA receptor antagonism by replacement and truncation variants of the conantokin peptides.

R C Klein1, S E Warder, Z Galdzicki, F J Castellino, M Prorok.   

Abstract

The characterization of conantokin-T (con-T), conantokin-R (con-R), and variants thereof, using the whole-cell patch clamp technique, was undertaken to evaluate the contribution of various residues towards the onset and recovery of N-methyl-D-aspartate (NMDA) receptor inhibition in cultured embryonic murine hippocampal neurons. The results obtained indicate that the two most C-terminal gamma-carboxyglutamic acid (Gla) residues of the conantokins, while not essential for activity, provided for more tenacious binding to the receptor. Specifically, con-T[gamma10K/gamma14K] and con-R[gamma11A/gamma15A] displayed 5.6- and 8.4-fold decreases in tau(off), respectively, compared to the parent peptides. For the truncated con-T variants, con-T[1-9/Q6G], and a sarcosine (Src)-containing species, con-T[1-9/G1Src/Q6G], the tau(off) was over 80- and 40-fold faster, respectively, compared to con-T. For the latter peptide, the coapplication of 300 microM spermine enhanced the onset rate constant from 3.1x10(3)M(-1) x s(-1) to 12.6x10(3)M(-1) x s(-1). From analysis of equilibrium dose-inhibition curves using the Cheng-Prusoff equation, a K(i) value of 1.1 microM for the peptide was obtained. Con-T[1-9/G1Src/Q6G] demonstrated an apparent competitive mode of inhibition relative to NMDA. Schild analysis of the data yielded an equilibrium dissociation constant of 2.4 microM for the interaction of con-T[1-9/G1Src/Q6G] with the receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684144     DOI: 10.1016/s0028-3908(01)00119-8

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Conantokins derived from the Asprella clade impart conRl-B, an N-methyl d-aspartate receptor antagonist with a unique selectivity profile for NR2B subunits.

Authors:  Konkallu Hanumae Gowd; Tiffany S Han; Vernon Twede; Joanna Gajewiak; Misty D Smith; Maren Watkins; Randall J Platt; Gabriela Toledo; H Steve White; Baldomero M Olivera; Grzegorz Bulaj
Journal:  Biochemistry       Date:  2012-05-30       Impact factor: 3.162

2.  Specific determinants of conantokins that dictate their selectivity for the NR2B subunit of N-methyl-D-aspartate receptors.

Authors:  Z Sheng; M Prorok; F J Castellino
Journal:  Neuroscience       Date:  2010-08-03       Impact factor: 3.590

Review 3.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

4.  NR2B-selective conantokin peptide inhibitors of the NMDA receptor display enhanced antinociceptive properties compared to non-selective conantokins.

Authors:  Cai Xiao; Yuanyuan Huang; Mingxin Dong; Jie Hu; Shuangshuang Hou; Francis J Castellino; Mary Prorok; Qiuyun Dai
Journal:  Neuropeptides       Date:  2008-11-07       Impact factor: 3.286

5.  Comparison of the neuropsychological mechanisms of 2,6-diisopropylphenol and N-methyl-D-aspartate receptor antagonist against electroconvulsive therapy-induced learning and memory impairment in depressed rats.

Authors:  Gang Liu; Chao Liu; Xue-Ning Zhang
Journal:  Mol Med Rep       Date:  2015-05-21       Impact factor: 2.952

6.  Antagonist properties of Conus parius peptides on N-methyl-D-aspartate receptors and their effects on CREB signaling.

Authors:  Shailaja Kunda; John Cheriyan; Michael Hur; Rashna D Balsara; Francis J Castellino
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.